Skip to main content

Table 3 Logistic regression model for predicting tumor response

From: FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients

 

n

Logistic regression OR [95% CI] (Pvalue)

Nodal status

  

  N0

51

1 (ref)

  N1

80

0.962 [0.446; 2.078] (0.922)

Grading

  

  G2–3

110

1 (ref)

  G1

20

1.203 [0.433; 3.339] (0.723)

Baseline tumor size

  

  > 2 cm

16

1 (ref)

  ≤ 2 cm

114

0.742 [0.242; 2.274] (0.601)

Age

  

  ≥ 65 years

100

1 (ref)

  < 65 years

31

1.189 [0.483; 2.924] (0.707)

Treatment

  

  LET

65

1 (ref)

  LET + ZOL

66

1.722 [0.827; 3.586] (0.147)